June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Impact of Duration of Exposure to Residual Intraretinal Fluid on Visual Function Outcomes in Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Rishi P Singh
    Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Rishi Singh, Aerie (F), Apellis (F), Bausch and Lomb (C), Genentech (C), Graybug (F), Novartis (C), Regeneron (C), Zeiss (C)
  • Footnotes
    Support  Funding by Regeneron Pharmaceuticals, Inc.
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 335. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rishi P Singh; Impact of Duration of Exposure to Residual Intraretinal Fluid on Visual Function Outcomes in Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2021;62(8):335.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : This analysis assessed the impact of duration of exposure to residual intraretinal fluid (IRF) on visual function outcomes in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGFs in the VIEW 1 and 2 trials.

Methods : This post hoc analysis included patients that received either ranibizumab 0.5 mg q4 weeks (Rq4) or intravitreal aflibercept injection 2 mg q4 weeks (IAI 2q4) or q8 weeks after 3 monthly doses (IAI 2q8) in VIEW 1 and 2. Duration of IRF from baseline through week 52 was evaluated as quartiles in both pooled treatment groups (Q1: ≤2 weeks, n=581; Q2: 3–≤8 weeks, n=411; Q3: 9–≤18 weeks, n=389; Q4: >18 weeks, n=423) and within each treatment group (Rq4, n=588; IAI 2q4, n=612; IAI 2q8, n=604). Visual function outcomes assessed included best corrected visual acuity (BCVA) and Visual Function Questionnaire 25 (VFQ-25) near activities and driving subscale scores.

Results : In the pooled analysis of treatment groups, mean BCVA gains from baseline at week 52 for Q1–Q4 were 10.9, 10.1, 9.4, and 6.6 (P<0.0001, Q4 vs Q1) letters, respectively. The corresponding proportions of patients with a ≥5 letters gain at week 52 were 71.4%, 72.0%, 72.6%, and 59.9% (P<0.05, Q4 vs Q1), and for those with a ≥5 letters loss at week 52 were 10.0%, 9.7%, 11.2%, and 16.5% (P<0.05, Q4 vs Q1), respectively. The mean change from baseline in the VFQ-25 near activities subscale score in Q1–Q4, respectively, were 9.7, 8.3, 7.2, and 5.3 (P<0.001, Q4 vs Q1) points, and for the driving subscale score were 3.0, 1.6, 2.4, and –2.4 (P<0.01, Q4 vs Q1) points. In the quartile analysis within each treatment group, the mean BCVA gains for Q1–Q4 were 11.0, 11.1, 9.3, and 5.8 (P<0.05, Q4 vs Q1) letters for Rq4; 10.7, 9.7, 9.2, and 7.7 letters for IAI 2q4; and 11.3, 11.2, 8.6, and 6.3 (P<0.05, Q4 vs Q1) letters for IAI 2q8, respectively.

Conclusions : In this analysis of patients treated with intravitreal aflibercept and ranibizumab in VIEW 1 and 2, longer duration of exposure to residual IRF was associated with lower visual acuity gain and worse vision-related quality of life outcomes.

This is a 2021 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.